Moxibustion for diarrhea-predominant irritable bowel syndrome

Abstract

Background: Irritable bowel syndrome (IBS) is commonly accompanied by intestinal dysfunction, and diarrhea-predominant irritable bowel syndrome accounts for approximately 23.4% of all cases of IBS. The purpose of this study was to evaluate the efficacy and safety of moxibustion in the treatment of diarrhea-predominant irritable bowel syndrome. Methods: According to the retrieval strategies, randomized controlled trials (RCTs) on moxibustion therapies for IBS-D will be obtained from the China National Knowledge Infrastructure, WanFang Data, Chinese Scientific Journals Database, PubMed, Embase, and Cochrane Library, regardless of publication date or language. Studies will be screened based on inclusion and exclusion criteria, and the Cochrane risk bias assessment tool will be used to evaluate the quality of the literature. The network meta-analysis will be performed with the Markov chain Monte Carlo method and carried out with Stata 14.2 and WinBUGS 1.4.3 software. Ultimately, the quality of the evidence obtained from the results will be evaluated. Results: This study will evaluate whether moxibustion therapy can effectively treat diarrhea-predominant irritable bowel syndrome. Conclusion: This study will provide evidence for whether moxibustion therapy is beneficial to the treatment of human diarrhea-predominant irritable bowel syndrome. INPLASY registration number: INPLASY202180003.

Efficacy of moxibustion in diarrhea-predominant irritable bowel syndrome model rats: a systematic review and meta-analysis

“…The titles and abstracts were screened, excluding the studies with inconsistent study subjects and interventions, resulting in 80 articles. Finally, the full text was read to exclude non-RCTs, duplicate publications, and studies with unavailable data, resulting in 21 RCTs in the final analysis (Figure 1) (Zhou, 2008;Zhou et al, 2009;Du, 2011;Zhang, 2012;Zhao, 2013;Zhang et al, 2017a;Zhang et al, 2017b;Wu, 2018;Fu et al, 2019;Jianan, 2019;Zheng et al, 2019;Tong, 2020;Wang et al, 2020;Ch et al, 2021;Shi et al, 2021;Wan, 2021;Wang, 2021;Wu et al, 2021;Li, 2022;Liao et al, 2022;Zhang et al, 2022).…”

“…Nine studies reported the AWR threshold capacity (Figure 2) (Zhang, 2012;Zhang et al, 2017a;Fu et al, 2019;Jianan, 2019;Zheng et al, 2019;Tong, 2020;Wang et al, 2020;Wu et al, 2021;Li, 2022). The meta-analysis results indicated significant heterogeneity (I 2 = 74%, p = 0.0002).…”

“…Six studies reported the rate of loose stool (Figure 3) (Wu, 2018;Tong, 2020;Wang et al, 2020;Ch et al, 2021;Wan, 2021;Wu et al, 2021). The meta-analysis showed significant heterogeneity (I 2 = 86%, p < 0.00001).…”

“…Three studies included IL-1β results (Figure 5) (Wu, 2018;Tong, 2020;Wang, 2021). The meta-analysis results indicated no heterogeneity (I 2 = 0%, p = 0.51).…”

“…Three studies investigated the TNF-α concentration (Figure 6) (Wu, 2018;Tong, 2020;Wan, 2021). The meta-analysis showed significant heterogeneity (I 2 = 84%, p = 0.002).…”